Filter posts

Uniting To Accelerate Pediatric Medicine

Drug companies inherently absorb significant risk when developing compounds and biologics for clinical use. A …

“Should the USPTO allow the patenting of living organisms?”

Most people associate patents with mechanical or electronic devices, new chemical substances, intricate machines or …

CTTI: Use of Central IRBs in Multi-Center Trials to Streamline Clinical Research

Multi-center clinical trials can provide high-quality, statistically-sound evidence to answer medical questions. Earlier this year, …

Prosensa's IPO and the Value of the BIO Investor Forum

Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the discovery and development of …

NCATS R&D Day Aimed At Linking Investors to Preclinical Drug Development Projects

On behalf of the National Center for Advancing Translational Sciences (NCATS), I invite BIO stakeholders …

Driving Innovation in Breast Cancer: Startup Challenge

The Avon Foundation (AF), National Institutes of Health National Cancer Institute (NCI) and Center for …

Involving Patients in the Research Process

According to the National Psoriasis Foundation, as many as 7.5 million Americans live with psoriasis, …

Propel Small Business Innovation through Tax Reform

As CEO of an emerging clinical-stage biotech company, I lose over $10 million each year. …

How the Orphan Drug Tax Credit Leverages MDA’s Fight against Rare Genetic Diseases

In the early 1950s, a small group of concerned parents, people with muscular dystrophy and …

When is the Evidence “Enough” to Make a Health Care Decision?

At any given time, work is taking place in hundreds of laboratories throughout the country …